Vaccine, Russia approves 'light' single-dose Sputnik. Putin opens the door to patent suspension

Russia, Sputnik light and the suspension of patents are the hot topics these days: the new drug is 79.4% effective compared to 91.6% for its two-dose version. And Putin opens the door to suspending vaccine patents

Moscow has given the green light for the ‘light’ version of its flagship vaccine against Covid-19, Sputnik V. The new drug will be administered in the first half of 2012.

The new drug will be administered in a single dose, as opposed to two doses for its basic version.

This was announced by Russia’s Ministry of Health, the Gamaleya National Research Centre of Epidemiology and Microbiology and the Russian Direct Investment Fund, which said that Sputnik Light is 79.4% effective compared to 91.6% for its two-dose version.


Meanwhile, Russia is reportedly ready to support the idea of suspending patents on coronavirus vaccines.

“There is an idea in Europe that, in my opinion, deserves attention: a derogation from intellectual property protection of patents for vaccines against Covid-19″, Russian President Vladimir Putin said during a videoconference meeting with Deputy Prime Minister Tatyana Golikova.

“This idea,” Putin added, “is in line with the rules of the World Trade Organisation, which provide for patent revocation in extraordinary circumstances,” such as the coronavirus pandemic.

Read Also:

Vaccine Revolution, US And EU Open Up About Patent Suspension. WHO: ‘This Is A Great Moment’

Russia Registers Sputnik Light, Single-Dose Vaccine Formula

In Brazil Import And Use Of Sputnik V Vaccine Are Refused

Vaccine, Moderna Announces Efficacy Against Brazilian And South African Variants


Agenzia Dire

You might also like